Although CCR5 signaling is not high in primary BC tumor sites, it could be theorized that CCR5 as a motility marker would be upregulated in migratory tumor-associated cells (TACs—CTCs and CAMLs) in circulation which could explain their motility [2, 26–28]. The gene discussed is CCR5; the disease is neoplasm.